Naslov
Longterm effect of American ginseng extract (Panax quinquefolius l.) on glycemic control in patients with type 2 diabetes

Autori
Mucalo, Iva

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
31st International Symposium on Diabetes and Nutrition

Mjesto i datum
Dubrovnik, Hrvatska, 27.06.2013. - 30.06.2013

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
american ginseng; glycemic control; diabetes

Sažetak
Objective: The objective of the present study was to test the efficacy and safety of 12 weeks of supplementation with the selected American Ginseng extract (AG) as an adjunct to usual therapy in people with type 2 diabetes, using a randomized, double-blind, placebo-controlled design. Methods: Each participant received either the selected AG preparation (ethanol extract) or placebo (500 mg/meal = 3 g/day) as an adjunct to their usual anti-diabetic therapy (diet and/or medications). Outcomes included measures of efficacy (glycated hemoglobin (HbA1c) -primary, fasting plasma glucose (FPG), fasting plasma insulin (FPI), and HOMA) ; safety (liver and kidney function) ; and compliance (returned capsules and body-weight). Results: Seventy-four participants with well-controlled type 2 diabetes (sex: 28 M: 46 F, age: 62, 9±9, 49, BMI: 32±5, 3, HbA1c: 7±1, 3), randomized to either intervention (n= 35) or control (n=39) group, completed the study. There was no change in the primary endpoint, HbA1c. Nevertheless, there was a trend toward lower HbA1c by 0.84% (P=0.836) compared to placebo. Furthermore, the participants remained well-controlled (HbA1c = 7.12%) throughout. The selected AG treatment also decreased FPG, FPI and HOMA by 4.42%, 11.54% and 18.84%, respectively, with no significant between-treatment difference (P=0.947, P=0.373, P=0.489, respectively). Within-treatment and between-treatment end differences of vascualr parameters were not statistically significant. Safety and compliance outcomes remained unchanged. Conclusion: Although clinical efficacy, as assessed by HbA1c, was not demonstrated, 12 weeks of supplementation with the selected AG treatment maintained good glycemic control in people with well-controlled type 2 diabetes without adverse effects. Further investigation of AG structure-function relationships may yield potential for clinical efficacy.

Izvorni jezik
Engleski

POVEZANOST RADA